GCG and Parkinson disease: Although its brain uptake is low (CSF/plasma ratio 0.01), its induced DPP-4 inhibition was sufficient to significantly elevate CNS incretin levels in line with levels in rodent studies associated with sitagliptin-mediated efficacy in a 6-OHDA model of PD [42].